Yimitasvir - HEC Pharm

Drug Profile

Yimitasvir - HEC Pharm

Alternative Names: DAG 181; Yimitasvir phosphate - HEC Pharm

Latest Information Update: 05 Apr 2017

Price : $50

At a glance

  • Originator HEC Pharm
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 10 Jan 2017 TaiGen Biopharmaceuticals and YiChang HEC ChangJiang Pharmaceutical form a joint venture, Dongguan HEC TaiGen Biopharmaceuticals
  • 30 Oct 2016 HEC Pharm completes a phase I trial (Treatment-naïve) in Hepatitis C in China
  • 22 Jul 2015 HEC Pharm enters into an agreement with Sunshine Lake Pharma to manufacture and commercialise yimitasvir
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top